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Introduction
Cervical cancer is the fourth most common cancer worldwide among women, with the number of 
new cases increasing from 493 243 in 2002 to 527 000 in 2012, and the number of deaths slowly 
decreasing from 274 000 in 2002 to 265 000 in 2008.1,2 These numbers are likely to be underestimated 
because given the lack of registration resources, cervical cancer deaths are usually under-reported 
in low-income countries. Cervical cancer is likely the most frequent cancer type among women 
aged 15–45 years in Africa.3
Over 90% of all cervical cancer cases are caused by persistent infection with high-risk human 
papillomaviruses (hr-HPV),3,4 which can lead to pre-cancerous lesions and invasive cervical 
carcinoma (ICC) if not treated. However, cervical cancer is preventable at relatively low cost 
through population-based screening approaches that ensure early detection of pre-cancerous 
lesions, followed by medical referral, timely diagnosis, safe treatment and follow-up.5
Co-infection with human immunodeficiency virus (HIV) in the sub-Saharan African countries 
increases the burden of cervical abnormalities because hr-HPV infections are more prevalent and 
Background: Cervical cancer is the fourth most common cancer worldwide among women, 
with the number of new cases increasing from 493 243 in 2002 to 527 000 in 2012. These numbers 
are likely to be underestimated because given the lack of registration resources, cervical cancer 
deaths are usually under-reported in low-income countries.
Aim: To describe the distribution of and trends in visual inspection with acetic acid (VIA) 
to detected cervical abnormalities in Swaziland by reviewing records of VIA examinations 
performed at two main hospitals in Swaziland between 2011 and 2014.
Setting: Mbabane Government Hospital and Realign Fitkin Memorial (RFM).
Methods: Records of cervical screening using VIA at the Mbabane government hospital and 
RFM hospital between 2011 and 2014 were retrieved. Positivity rates (PRs) of VIA with 95% 
confidence intervals (95% CI) were calculated and used as proxies of cervical abnormalities. 
Odds ratios of the association between VIA-detected cervical abnormalities and human 
immunodeficiency virus (HIV) status were estimated using logistic regressions.
Results: VIA was positive in 1828 of 12 151 VIA records used for analysis (15%, 95% CI: 14.4–
15.7). VIA was positive in 9% (36 of 403) women under the age of 20, in 15.5% (1714 of 11 046) 
of women aged 20–49 years and in 11.1% (78 of 624) of women aged 50–64 years. A decreasing 
trend of VIA positivity was observed over time at both screening centres (p for trend < 0.001). 
Of 2697 records with Papanicolaou results, 20% (67 of 331) VIA-positives and only 5% (114 of 
2366) VIA negatives had high-grade squamous intraepithelial lesion. Among 4578 women 
with reported HIV status, 1702 were HIV-positive (37.2%, 95% CI: 35.8–38.6). The prevalence 
of HIV in VIA-positive women was 62.5% (95% CI: 58.7–66.2), almost double that among VIA-
negative women (33.0%, 95% CI: 31.6–34.5) and that among all women screened (p < 0.001). 
HIV-positive women were 3.4 times more likely to have cervical abnormalities on VIA than 
HIV-negative women (OR: 3.4, 95% CI: 2.8–4.0, p < 0.01).
Conclusion: The high VIA PRs observed over four years in this study may reflect the prevalence 
of cervical abnormalities, in particular, in HIV-positive women. VIA is not a robust screening 
test, but it can play a major role in strengthening and expanding cervical cancer screening 
prevention programmes in resource-limited countries.
Distribution of cervical abnormalities detected by  
visual inspection with acetic acid in Swaziland,  
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persistent among HIV-positive women.6 A significant number 
of HIV-positive women are now accessing life-prolonging 
antiretroviral therapy (ART); therefore, there are more high-
risk women living longer at an increased risk of developing 
ICC in developing countries.6
About 80% of cervical cancers in developing countries like 
Swaziland are diagnosed at an advanced stage, resulting 
in poor prognosis.7 The challenge in these countries is to 
implement and maintain adequate cervical screening with very 
limited resources (e.g. infrastructure and health professionals).
The use of Papanicolaou (Pap) smears for early detection of 
cervical cancer over the past 50 years has led to more than a 
70% decrease in the mortality rates in high-income countries, 
compared to a 19% decrease in low-income countries.8 In 1983, 
Pap was implemented at the Swaziland Central Public Health 
Laboratory, which remains the only cytology laboratory in the 
country. This laboratory receives cervical smears of mainly 
symptomatic women attending health institutions from all 
over the country. Screening was offered only to a small 
proportion of women in the two main cities of the country: 
Mbabane and Manzini. In a report of the status of cytology 
in Swaziland, 5113 of 11 701 (44%) Pap smears, adequate for 
diagnosis, received at the Central Public Health Laboratory 
between 2004 and 2006 were abnormal.9 The prevalence of 
cytological high-grade squamous intraepithelial lesion (HSIL) 
was 12% (602 of 5113), more than five times the usually 
reported 1% – 2% in asymptomatic screening populations.9,10 
Since then, many international studies and programmes have 
provided evidence of the feasibility and cost-effectiveness of 
screen-and-treat approaches for cervical cancer prevention in 
countries with limited resources and difficult scenarios.11,12
Visual inspection of the cervix after the application of acetic 
acid (VIA) is a more attractive and feasible screening strategy 
for cervical cancer precursors detection than cytology in 
low-income countries where high-quality cytology-based 
programmes are difficult to establish or maintain.13 Visual 
inspection with acetic acid is not expensive, can be performed 
by non-medical health workers and its results are available 
immediately, allowing treatment of screened positives the 
same day. In 2009, to fast track the early detection of cervical 
lesions and facilitate the extension of cervical cancer 
prevention services in both urban and rural areas, the 
Swaziland Ministry of Health incorporated the use of VIA 
followed by treatment with cryotherapy in the national 
cervical cancer prevention programme.
Cervical cancer screening and 
management programme in 
Swaziland
In 1983, the government of the Kingdom of Swaziland 
(Ministry of Health) introduced the Pap smear for cervical 
cancer screening at the National Referral Laboratory, which 
remains the only functional cytology laboratory in the 
country. This laboratory receives cervical smears of mainly 
symptomatic women attending health institutions from all 
over the country.
However, many international researches and programmes 
have presented evidence of the feasibility and cost-
effectiveness of ‘screen-and-treat’ approaches for cervical 
cancer prevention in countries of scarce resources. Visual 
inspection of the cervix after the application of acetic acid is a 
more attractive and feasible screening approach for cervical 
cancer precursors detection than cytology in developing 
countries where high-quality cytology-based programmes 
are hard to institute or sustain.13 Visual inspection with acetic 
acid is so cheap and user-friendly, can be achieved by any 
trained nurse and its results are available immediately, 
allowing treatment of screened positives the same day. In 
2009, to quicken the early detection of cervical lesions 
and facilitate the extension of cervical cancer prevention 
services across four political regions, the Swaziland Ministry 
of Health incorporated the use of VIA, followed by treatment 
with cryotherapy to the national cervical cancer prevention 
programme. Other treatment methods used include loop 
electrosurgical excision procedure (LEEP), which is the 
treatment of choice when a lesion is too large for the cryoprobe 
or involves the endo-cervical canal or when a histological 
specimen is needed.14 For cervical cancer treatment, according 
to the national cervical cancer guidelines, patients may be 
diagnosed by clinicians at clinic level or health centre level 
and then referred to a regional hospital, which subsequently 
refers to a National Referral Hospital for further 
investigations.14 However, most of the necessary tests, staging 
equipment and treatments are not available in Swaziland. 
Therefore, almost all cervical cancer patients are transferred 
and treated in South Africa, so a heavey economic burden is 
experienced by the country.
Therefore, we conducted a retrospective study to describe 
the distribution and trends of VIA-detected cervical 
abnormalities over four years in two hospitals that pioneered 
the implementation of the VIA programme in Swaziland.
Materials and methods
Records of cervical screening using VIA at the Mbabane 
Government Hospital and the Realign Fitkin Memorial 
(RFM) hospital between 2011 and 2014 were retrieved. Visual 
inspection with acetic acid visits are recorded on designed 
record books. Nurses performing VIA registered their results 
themselves and transfer the data to an Excel database with 
some clerical support.
Following the Ministry of Health guidelines,14 VIA was 
reported as: (1) negative if no acetowhite change is observed, 
(2) positive if an acetowhite area is noticed in the 
transformation zone and (3) suspicious for invasive cancer if 
a growth or ulcerative lesion is observed.
Visual inspection with acetic acid records include the date 
and result of screening, as well as the age and area of 
residence of women screened at both centres. No histology 
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data were available from either centre. Age was categorised 
into five groups: 15–19, 20–29, 30–39, 40–49 and 50–64, and 
records with ages less than 15 and over 64 years were 
excluded from the analyses. As the number of screened 
women younger than 20 years was small, this group was 
merged with those 20–29 years, or age was split into two 
groups, less than 30 years and 30–64 years, for certain analyses.
In addition, information on Pap smears and the HIV 
status from women screened at the Mbabane hospital was 
retrieved from hospital clinical records whenever available. 
Papanicolaou results were classified following the Bethesda 
system15 and further grouped into four (or three) categories 
for analyses: negative, atypical typical squamous cells of 
undetermined significance (ASCUS) and/or atypical 
glandular cells of undetermined significance (AGUS), low-
grade squamous intraepithelial lesion (LSIL) (or ASCUS 
and/or LSIL) and HSIL or worse (HSIL+) for statistical 
analysis. Papanicolaou HSIL was considered a proxy of high-
grade cervical disease and was used to calculate positive and 
negative predictive values of VIA.
HIV status collected from clinical data could be based on 
recorded ART prescriptions or could be self-reported at the 
time of screening. None of these data were available for the 
RFM hospital.
Visual inspection with acetic acid positivity included positive 
and suspicious for invasive cancer results. Positivity rates 
(PRs) of VIA with 95% confidence intervals (95% CI) were 
calculated and used as proxies of cervical abnormalities, 
overall, by age, by Pap results, by screening centre and by 
year and month of screening. Visual inspection with acetic 
acid PRs by these characteristics was compared using 
the t-test for proportions, or the score test for trends as 
appropriate.
The prevalence of HIV (with 95% CI) was estimated overall 
by VIA result and age. Odds ratios of HIV status for VIA 
result (positive vs. negative) were estimated overall and by 
age using logistic regressions. Potential interactions were 
evaluated using the likelihood ratio test (LRT). Statistical 
analysis was carried out using Stata 14.0 SE.
Ethical consideration
This study was approved by the Scientific Ethics Committee 
of Swaziland (SEC) (reference no.: MH599C/FW00015267/
IRB0009688) and the Biomedical Research Ethics Committee 
of the University of KwaZulu-Natal (BREC) (reference no.: 
BE 242/14). As the study was a retrospective study, consent 
to participate was not applicable.
Results
A total of 13 561 records of women who attended cervical 
screening from January 2011 to October 2014 at the Mbabane 
Government Hospital and up to June 2014 at the RFM 
hospital were reviewed. Records without conclusive VIA 
results (n = 1254) and those from women outside the age 
range of 15–64 years (n = 156) were excluded (Figure 1).
Table 1 shows the main characteristics of women screened 
with VIA, overall, and separately by VIA abnormal results: 
positive or suspected cancer. Of the 12 151 VIA exams 
considered for analysis, 76% were performed in women aged 
20–39 years, 60% in women from the Manzini region, 32% in 
those from Hhohho, 6% in women from Lubombo and 2% in 
those from Shiselweni. The number of exams per month at 
13 561 screening
records retrieved
- 1254 with results not 
   available
- 131 woman aged 65+
- 25 with unkown age
12 151
women 15–64y
with VIA results
Mbabane
(n = 5209)
4487 (86.1%)
VIA negave
RFM
(n = 6942)
5836 (84.1%)
VIA negative
722 (13.9%)
VIA posive
- 602 abnormal
- 120 suspected
  cancers
1106 (15.9%)
VIA positive
- 1097 abnormal
- 9 suspected 
  cancers
RFM, Realign Fitkin Memoria; VIA, visual inspection with acetic acid.
FIGURE 1: Total number of records of women who attended cervical screening 
from 2011 to 2014 at Mbabane Government Hospital and Realign Fitkin 
Memorial hospital, Swaziland.
TABLE 1: Number of visual inspections with acetic acid (VIA) exams conducted, 
and percentages of women with VIA-positive results by different characteristics.
Characteristics No. of  
VIA exams
% VIA abnormal results
VIA positive Suspected cancer
No. % No. (%)
Age
15–19 403 3.3 35 8.9 1 0.3
20–29 4866 40.0 710 14.6 13 0.3
30–39 4351 35.8 710 16.3 40 1.1
40–49 1829 15.1 202 11.0 31 1.8
50–64 702 5.8 42 6.0 35 5.1
Region†
Hhohho 3884 32.0 462 11.9 63 1.6
Lubombo 710 5.8 134 18.9 10 1.4
Manzini 7301 30.1 1067 14.6 50 0.7
Shiselweni 238 2.0 35 14.7 4 1.7
Hospital
Mbabane 5209 42.9 602 11.6 120 2.3
RFM 6942 57.1 1097 15.8 9 0.1
Year of screening
2011 1951 16.1 422 21.6 17 0.9
2012 3235 26.6 472 14.6 33 1.0
2013 4437 36.5 596 13.4 44 1.0
2014 2528 20.8 209 8.3 35 1.4
Total 12 151 - 1699 14.0 129 1.1
RFM, Realign Fitkin Memorial; VIA, visual inspection with acetic acid.
†, Data on region of residence were not available for 18 women in the Mbabane hospital.
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Mbabane over 2011 was very small, while at RFM, more than 
100 VIAs were performed monthly from March 2011 onwards; 
a larger proportion (37%) of VIA exams were conducted in 
2013 than in other years.
Table 2 shows the VIA PR overall by hospital and by age. The 
overall VIA PR was 15% (1828 of 12 151 women aged 15–64 
years) with 1.1% of the exams classified as suspicious for 
cancer. The overall VIA PR at RFM was 2% higher than that 
of Mbabane (15.9%, 95% CI: 15.1%–16.8% at RFM, 13.9%, 95% 
CI: 12.9–14.8 at Mbabane, p = 0.02); and this was mainly 
because of higher rates in women aged 30 and above (17.5%, 
95% CI: 16.4–19.0 at RFM vs. 13.4%, 95% CI: 12.3–14.6 for 
those aged 30–64 at Mbabane, p < 0.001). No significant 
overall trend of VIA PRs by age was observed (p for 
trend=0.15). Visual inspection with acetic acid PRs were 
about 15% in women less than 40 and then decreased to 9% in 
those 50–64 years attending the Mbabane hospital, while VIA 
PRs at RFM overall increased from 8% in women aged 15–19 
years to 18% again in those 50 years and older.
Figure 2 shows the distribution of VIA PRs over time by 
hospital, while VIA PRs at RFM decreased clearly over time 
from 23.6% in 2011 to 9.5% in 2014, such a trend was not evident 
in exams conducted at Mbabane. However, after excluding 
months when less than 100 VIAs were performed, the PRs at 
Mbabane decreased from 14.8% in 2011 to 9.7% in 2014.
There were 3327 Pap smears with results at Mbabane over the 
four years; 630 (18.9%) were unsatisfactory and among 2697 
satisfactory smears, 84% of them were negative, 251 (9%) 
were ASCUS and/or LSIL and 181 (7%) were HSIL or worse 
(HSIL+). Visual inspection with acetic acid was positive in 
only 182 (8%) women with negative Pap smears, but 11 (6% of 
182) exams were considered suspicious for cancer. Among 432 
women with abnormal cytology, 34% (149) were VIA positive; 
in particular, of 181 women with HSIL, 67 (37%) were positive 
on VIA, and 15 (8%) were considered suspected cancers. The 
percentage of Pap HSIL increased with age from 5% in women 
less than 30 years to 10% in women less than 50 years and 
older and a similar trend was observed for VIA classified as 
suspicious for cancers which increased from 0.8% in the 
youngest age group to 6% in the older one (Table 3).
Of 4578 women with known HIV status, 1702 (37.2%, 95% 
CI: 35.8–38.6) were HIV-positive; VIA was positive in 8% of 
HIV-negative women and in 24% of HIV-positive women. 
The highest HIV prevalence was observed among women 
of 30–39 years (45%), HIV prevalence decreased afterwards, 
independently of VIA result (Supplementary Figure 3).
LSIL, low-grade squamous intraepithelial lesion; HSIL, high-
grade squamous intraepithelial lesion; Pap, Papanicolaou; 
VIA, visual inspection with acetic acid; HIV, human 
immunodeficiency virus.
There were 2509 women with adequate Pap smears and 
known HIV status, 410 (10%) of them had abnormal cytology 
(232 ASCUS and/or LSIL and 178 HSIL) and 243 (59% of 410) 
were HIV-positive.
In the absence of histology results, assuming PAP HSIL+ as a 
proxy of high-grade cervical disease and therefore as gold 
standard, the sensitivity and specificity of VIA to detect Pap 
HSIL were 37% (95% CI: 30.0–44.5) and 89.5% (95% CI: 88.2–
90.7), while the positive and negative predictive values of VIA 
were 20.2% (95% CI: 16.0–25.0) and 95.2% (95% CI: 94.2–96.0).
In a multivariate logistic model including age, cytology 
abnormalities (Pap ASCUS+) and HIV positivity, after 
adjusting for the other two factors, HIV-positive women were 
2.9 times more likely to have a positive VIA (OR: 2.9, 95% 
CI: 2.3–3.8) than HIV-negative women, similarly, compared to 
women with normal Pap smears; those with abnormal cytology 
were 4.8 times more likely to be VIA-positive (Table 4).
TABLE 2: Visual inspection with acetic acid results by age and screening centre, 2011–2014.
Screening 
centre
VIA result† Age group All ages
15–19 % 20–29 % 30‒39 % 40–49 % 50–64 % n %
All Negative 367 91.1 4142 85.1 3595 82.6 1595 87.2 624 88.9 10 323 85.0
Positive 36 8.9 724 14.9 756 17.4 234 12.8 78 11.1 1828 15.0
Mbabane Negative 47 85.5 1435 85.3 1600 84.2 903 88.9 502 90.6 4487 86.1
Positive 8 14.5 248 14.7 301 15.8 113 11.1 52 9.4 722 13.9
RFM Negative 320 92.0 2707 85.1 1995 81.4 692 85.1 122 82.4 5836 84.1
Positive 28 8.0 476 14.9 455 18.6 121 14.9 26 17.6 1106 15.9
VIA, visual inspection with acetic acid; RFM, Realign Fitkin Memorial
†, VIA positive includes positive and suspicious for invasive cancer results.
25
20
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i
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 (%
)
5
0
2011
Year of screening
2012 2013 2014
95% CI
Mbabane
RFM
RFM, Realign Fitkin Memorial; VIA, visual inspection with acetic acid.
†, Few women attended screening before September 2011 at Mbabane and before March 2011 
at RFM. Screening data were only available up to October at Mbabane and up to June at RFM.
‡, Significant overall trend of VIA PRs over time and at RFM hospital (p for trend < 0.001).
FIGURE 2: Visual inspection with acetic acid positivity rates (95% confidence 
interval) over time by hospital.†‡
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Discussion
In this retrospective study, we summarised the distribution 
of cervical abnormalities based on VIA results among 13 561 
women who attended cervical screening in two main 
hospitals of Swaziland from 2011 to 2014, following the 
implementation of VIA in 2009 as part of the national cervical 
screening programme. Despite not having data for some 
months in 2014, it was observed that after the introduction of 
VIA in each hospital, the number of VIA exams increased 
annually from 1951 in 2011 to 4437 in 2013, when the largest 
proportion of VIA exams were conducted (38.8% at Mbabane, 
34.8% at RFM).
Our study showed an overall VIA PR of 15% (95% CI: 14.4–
15.7) among women aged 15–64 years with 1.1% of VIA exams 
classified as suspicious for cervical cancer. In addition, there 
was a much smaller proportion of VIA classified as suspected 
cancer in RFM than at Mbabane (0.1% v 2.3%). These differences 
could be explained by differences in the criteria used to classify 
exams and by observer variability. Visual inspection with 
acetic acid exams were conducted by one single nurse in each 
centre, both of them were trained at the same time by experts 
in Zambia; therefore, it is unlikely that differences are because 
of VIA positivity definition. In addition, there are potential 
issues of overcall versus under-call between the two nurses. 
It is known that VIA PRs vary largely compared to other 
screening test results and that VIA heavily depends on human 
judgement.16 As only one nurse per centre performed VIA, it is 
likely that the differences represent observer variability. It 
has been proposed that this variability can be lessened with 
the establishment of VIA proficiency schemes that can provide 
certification to VIA providers. Unfortunately, in poor-resource 
settings, the availability of training and supervision may 
be limited, and other options to ensure quality of VIA should 
be explored. Nevertheless, overall observed VIA PRs are 
within limits of previous studies.17,18,19
TABLE 4: Odds ratios (95% CI) relating human immunodeficiency virus status and 
Pap results to visual inspection with acetic acid positivity.
Results No. of 
women
No. of 
VIA+
VIA+  
(%)
UOR 95% CI AOR 95% CI
HIV-negative 2876 241 8.4 1.0 - 1.0 -
HIV-positive 1702 402 23.6 3.4i 2.8–4.0 2.9 2.3–3.8
Pap negative 2265 182 8.0 1.0 - 1.0 -
Pap ASCUS+ 432 149 34.5 6.0j 4.7–7.7 4.8 3.7–6.3
VIA+, VIA positive including positive and suspicious for invasive cancer; No., number; UOR, 
unadjusted odds ratio; AOR, odds ratio adjusted for HIV status; Pap ASCUS+, result and age, 
model based on 2509 observations with complete data; VIA, visual inspection with acetic 
acid; Pap, Papanicolaou.
†, HIV-positive women significantly associated with VIA-positive; ‡, Pap ASCUS+ women 
significantly associated with VIA-positive.
TABLE 3: Papanicolaou results and human immunodeficiency virus status by visual inspection with acetic acid result and age at Mbabane, 2011–2014.
Variables VIA results Pap adequate results HIV available status
All (N = 5209) VIA Positive VIA SC All (N = 2697) Pap ASCUS+ Pap HSIL+ All (N = 4578) HIV-positive
No. %† No. %‡ No. %‡ No. %† No. %‡ No. %‡ No. %† No. %‡
VIA
Negative 4487 - - - - - 2366 87.7 283 12.0 114 4.8 3935 85.9 1300 33
Positive 602 - - - - - 302 11.2 131 43.4 52 17.2 539 11.8 334 62
Suspected cancer 120 - - - - - 29 1.1 18 62.1 15 51.7 104 2.3 68 65.4
Pap
Negative 2265 84 182 8.0 11 0.5 - - - - - - 2099 68.2 676 32.2
ASCUS and/or LSIL 251 9.3 82 32.7 3 1.2 - - - - - - 232 7.5 149 64.2
HSIL 181 6.7 67 37.0 15 8.3 - - - - - - 178 5.8 94 52.8
Inadequate 630 - 124 19.7 36 5.7 - - - - - - 569 18.5 235 36.5
Not available 1882 - 267 14.2 55 2.9 - - - - - - 1500 - 548 36.5
HIV status
Negative 2876 62.8 241 8.4 36 1.3 1590 63.4 167 10.5 84 5.3 - - - -
Positive 1702 37.2 402 23.6 68 4.0 919 34.6 243 26.4 94 10.2 - - - -
Not available 631 - 79 12.5 16 2.5 188 - 22 11.7 3 1.6 - - - -
Age
15–29 1738 33.4 256 14.7 14 0.8 983 36.5 140 14.2 51 5.1 1574 34.4 534 33.9
30–39 1901 36.5 301 15.8 40 21.1 955 35.4 160 16.8 64 6.7 1678 36.7 760 45.3
40–49 1016 19.5 113 11.1 31 3.0 535 19.8 92 17.2 43 8.0 858 18.7 300 35.0
50–64 554 10.6 52 9.4 35 6.3 224 8.3 40 17.9 23 10.3 468 10.2 108 23.1
Note: All include women with corresponding available results. VIA+ includes positive and suspicious for invasive cancer results. PAP ASCUS+ includes paps reported as ASCUS, LSIL and HSIL and 
cancer. Pap HSIL includes only paps reported as HSIL or cancer.
VIA, visual inspection with acetic acid; Pap, Papanicolaou.
†, Percentages of those with a particular test result (or age group) = No. with particular result/(No. in ‘ALL’ – ‘Inadequate and/or Not available’ test results).
‡, Percentage of those in row who were positive on each test (or age group).
100
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VIA, visual inspection with acetic acid.
FIGURE 3: Human immunodeficiency virus prevalence by age and visual 
inspection with acetic acid results at Mbabane, 2011–2014
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The prevalence of HIV was 37.2% among 4578 women aged 
15–64 years with known HIV status (self-reported or based on 
clinical records) attending the Mbabane hospital. Even though 
HIV status was only available for one hospital, the results are 
likely to be representative of all women in Swaziland, as they 
are similar to those reported by the 2011 Swaziland HIV 
Incidence Measurement Survey (SHIMS), in which the HIV 
prevalence in women aged 18–49 years was 39%.20
It is clear that cervical abnormalities are more prevalent 
among HIV-positive women than among HIV-negative 
women. A review of studies published before 2007 that 
evaluated the association between HIV infection, HPV 
infection and cervical neoplasia, and the impact of using 
highly active ART (HAART) on the association, reported 
ratios of the prevalence of HPV infection, LSIL and HSIL in 
HIV-positives compared to HIV-negatives.21 Among women 
who participated in 11 studies in Africa, prevalence ratios 
ranged between 1.0 and 3.6 for HPV, between 1.6 and 8.8 
for LSIL and 3.1 and 5.1 for HSIL; thus, prevalence ratios 
increased by grade of abnormality, confirming that HIV 
infection is strongly associated with higher HPV-persistent 
infection, which leads to higher prevalence of squamous 
intraepithelial lesions, and eventually to higher rates of ICC.21 
However, the evidence was not that clear for HAART use, 
and although it seems that HAART has little or no beneficial 
effect on the natural history of cervical lesions in HIV-positive 
women, its use increases their life expectancy.21 In addition, as 
life expectancy increases, so does the likelihood of developing 
cervical cancer if precancer lesions are not detected and 
treated on time. In low- and middle-income countries, 
organised cervical screening does not exist or has usually 
been unsuccessful. Even when there is enough infrastructure 
and human resources available, the organisation of screening 
activities such as inviting women, returning results on time 
and, most importantly, ensuring that women with cervical 
lesions are treated, are difficult to achieve. It demanding less 
complex schemes, such as VIA, followed by cryotherapy 
(see-and-treat) preferably carried out in one single visit. A 
recent study conducted in three countries: Guyana in South 
America, Cote d’Ivoire in West Africa and Tanzania in East 
Africa, where 34 921 women were screened using VIA in a 
single-visit approach, HIV-positive women had higher odds 
of being VIA positive (OR: 1.9, 95% CI 1.8–2.2) and of having 
large lesions requiring referral (OR: 1.9, 95% CI: 1.5–2.5) 
than HIV-negative women.22 These results, although less 
strong, are in line with ours as we found that HIV-positive 
women were over three times more likely to have cervical 
abnormalities detected at VIA than HIV-negatives (OR: 3.4: 
95% CI: 2.8–4.0), and that this HIV effect was stronger among 
women of 30 years and older (OR: 4.2, 95% CI: 3.3–5.2), than 
among those younger than 30 (OR: 2.5, 95% CI: 1.9–3.3).
A subset of 2697 records retrieved from the Mbabane hospital 
contained Pap results. The overall percentage of cytological 
abnormalities was 16% (95% CI: 14.7–17.5); 3% of them were 
ASCUS and/or AGUS, 6% LSIL and 7% HSIL or cancer). In a 
previous report of 12 323 smears read at the Central Public 
Health Laboratory (CPHL), the proportion of cytological 
abnormalities was 44%, almost threefold ours9; however, 
while we have retrieved records of mostly asymptomatic 
women attending screening, most smears read at the CPHL 
were from symptomatic women. We further cross-tabulated 
VIA with Pap results, observing that the percentage of VIA 
positive results increased by cytological grade; from 8% in 
women with negative cytology, 27% in those with ASCUS 
and/or AGUS, 35.8% in LSIL and 37% in those with HSIL or 
cancer. It is important to highlight that although there were 
only 29 VIAs classified as suspected for cancer with known 
Pap results, 11 (38%) of them were on women with negative 
cytology and 15 (52%) in those with HSIL+. Local guidelines 
indicate that these women should be referred to colposcopy 
and biopsy and should be treated based on histology results. 
A number of problems arise with these cases: there are only 
two pathologists (recently appointed) in the country, very few 
gynaecologists and no radiotherapy facilities in Swaziland. 
Invasive cervical cancer cases are reported to a referral scheme 
called Phalala, whose committee decides whether a cancer 
case is referred for chemotherapy and radiotherapy to South 
Africa. This process can take up to four months, and the 
decision for referral, the treatment given and the clinical status 
after treatment are generally not reported back to the local 
doctor. Thus, we do not know the final diagnoses of these 
women and whether they were treated or not.
To our knowledge, this study represents the first evaluation 
of VIA results after its introduction in the Swaziland National 
Cervical Screening programme. The main strength of our 
study relies on the large number of VIA screens performed 
in women, residents from all political regions of the 
country, who attended two major hospitals over four years. 
However, although the records retrieved, we assumed, were 
representative of all women in Swaziland, we cannot rule out 
potential information and reporting bias, as we have used 
routine-collected data. Therefore, we accept that biases 
may have been greater because this is an analysis based on 
routine-collected data, that is, we did not have any control 
over the data collection. In fact, we were able to retrieve data 
on Pap smears and HIV-reported status only from a small 
subset of women. In addition, although we can assume 
that at least in the two hospitals included in this report 
adherence to the screen-and-treat protocol was high, and that 
the majority of VIA positives eligible for cryotherapy were 
treated, we were unable to retrieve data to confirm this. 
Another major limitation of our study is the lack of colposcopy 
and histological confirmation of disease, which was non-
existent, as only recently two pathologists have been 
appointed in the country. We still estimated the performance 
of VIA using Pap HSIL as gold standard; in this scenario, it is 
of concern the very low sensitivity of VIA, 37%, highlighting 
that there may be a number of women with cervical disease 
left untreated. Such may be because of challenges of 
implementing screening such as the low number of health 
service providers and limited training opportunities.
There is overwhelming evidence that human papillomavirus 
(HPV) DNA testing is more sensitive than cytology and VIA 
for the detection of high-grade cervical lesions.23,24 It has also 
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been demonstrated that a negative HPV test provides long-
term protection against cervical neoplasia and stronger 
reassurance of not developing invasive cancer, and this 
protection can be translated into fewer screens over life, 
facilitating adequate screening of vulnerable populations in 
particular in low- and middle-income countries. Nevertheless, 
even within HPV-based screening, the major challenges 
associated with the process of screening mentioned above 
will remain; in particular, those associated with ensuring that 
women receive their screening results and are properly 
evaluated and treated. The difficulties associated with 
following-up women could be reduced by using HPV testing 
within screen-and-treat (HPV and cryotherapy) schemes, 
with or without VIA triage, that should be considered as an 
alternative to VIA-based screening once a validated HPV test 
becomes affordable enough to be introduced and scaled up in 
countries with limited resources.
Conclusion
In conclusion, based on our findings, cervical abnormalities 
represent a public health problem that needs to be addressed 
urgently by strengthening, and expanding the existing 
cervical cancer screening in the country, with a priority 
among HIV-positive women. Lobbying and advocating for 
the development of a cervical cancer screening policy, as well 
as the introduction of HPV vaccine at national level is needed 
to implement a comprehensive cervical cancer prevention 
programme. The results found in this retrospective study call 
for improved health education programmes on cervical 
cancer screening and potential-associated risk factors such as 
sexually transmitted infections, in particular HPV, among 
high-risk groups. It also calls for the evaluation of alternative 
screening schemes that include HPV testing that can offer 
further reassurance to screened negatives of not developing 
cervical cancer for several years. Nonetheless, population-
based screening using low cost VIA, if followed by treatment 
of VIA positives, is currently the best screening alternative in 
limited-resourced settings until a validated HPV test becomes 
affordable.
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